TX HB3086

Requires pharmaceutical drug manufacturers to submit annual reports by January 15th to the state health department with current wholesale acquisition cost information for all FDA-approved prescription drugs sold in Texas

Mandates additional reporting for drugs with price increases of 40% or more over three years, or 15% or more in a single year, including whether the drug is brand name or generic, factors causing the increase, and aggregate research and development costs from SEC Form 10-K filings

Requires manufacturers to report names of drugs FDA-approved in the previous three years and drugs that lost patent exclusivity in the U.S. during that same period for any drug meeting the price increase thresholds

Changes administrative penalties from discretionary ("may") to mandatory ("shall") for violations of reporting requirements under this chapter

Takes effect September 1, 2025, with the Health and Human Services Commission directed to adopt implementing rules as soon as practicable